Goldhirsch, A., Glick, J.H., Gelber, R.D., Coates, A.S. & Senn, H.J. Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer. J. Clin. Oncol. 19, 3817–3827 (2001).
Pritchard, K.I. et al. HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N. Engl. J. Med. 354, 2103–2111 (2006).
Easton, D.F. et al. Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 447, 1087–1093 (2007).
Tommiska, J. et al. Breast cancer individuals with p53 Pro72 homozygous genotype have a poorer survival. Clin. Cancer Res. 11, 5098–5103 (2005).
Toyama, T. et al. Association of TP53 codon 72 polymorphism and the outcome of adjuvant therapy in breast cancer individuals. Breast Cancer Res. 9, R34 (2007).
Siegel, D. et al. NAD(P)H:quinone oxidoreductase 1: role as a superoxide scavenger. Mol. Pharmacol. 65, 1238–1247 (2004).
Beyer, R.E. et al. The role of DT-diaphorase in the maintenance of the reduced antioxidant form of coenzyme Q in membrane systems. Proc. Natl. Acad. Sci. USA 93, 2528–2532 (1996).
Siegel, D., Bolton, E.M., Burr, J.A., Liebler, D.C. & Ross, D. The reduction of alpha-tocopherolquinone by human NAD(P)H: quinone oxidoreductase: the role of alpha-tocopherolhydroquinone as a cellular antioxidant. Mol. Pharmacol. 52, 300–305 (1997).
Winski, S.L. et al. Relationship between NAD(P)H:quinone oxidoreductase 1 (NQO1) levels in a series of stably transfected cell lines and susceptibility to antitumor quinones. Biochem. Pharmacol. 61, 1509–1516 (2001).
Anwar, A. et al. Interaction of human NAD(P)H:quinone oxidoreductase 1 (NQO1) with the tumor suppressor protein p53 in cells and cell-free systems. J. Biol. Chem. 278, 10368–10373 (2003).
Asher, G., Lotem, J., Cohen, B., Sachs, L. & Shaul, Y. Regulation of p53 stability and p53-dependent apoptosis by NADH quinone oxidoreductase 1. Proc. Natl. Acad. Sci. USA 98, 1188–1193 (2001).
Asher, G., Lotem, J., Kama, R., Sachs, L. & Shaul, Y. NQO1 stabilizes p53 through a distinct pathway. Proc. Natl. Acad. Sci. USA 99, 3099–3104 (2002).
Asher, G., Lotem, J., Sachs, L., Kahana, C. & Shaul, Y. Mdm-2 and ubiquitin-independent p53 proteasomal degradation regulated by NQO1. Proc. Natl. Acad. Sci. USA 99, 13125–13130 (2002).
Iskander, K. et al. Lower induction of p53 and decreased apoptosis in NQO1-null mice lead to increased sensitivity to chemical-induced skin carcinogenesis. Cancer Res. 65, 2054–2058 (2005).
Long, D.J. II et al. NAD(P)H:quinone oxidoreductase 1 deficiency increases susceptibility to benzo(a)pyrene-induced mouse skin carcinogenesis. Cancer Res. 60, 5913–5915 (2000).
Ahn, K.S., Sethi, G., Jain, A.K., Jaiswal, A.K. & Aggarwal, B.B. Genetic deletion of NAD(P)H:quinone oxidoreductase 1 abrogates activation of nuclear factor-kappaB, IkappaBalpha kinase, c-Jun N-terminal kinase, Akt, p38, and p44/42 mitogen-activated protein kinases and potentiates apoptosis. J. Biol. Chem. 281, 19798–19808 (2006).
Kelsey, K.T. et al. Ethnic variation in the prevalence of a common NAD(P)H quinone oxidoreductase polymorphism and its implications for anti-cancer chemotherapy. Br. J. Cancer 76, 852–854 (1997).
Nioi, P. & Hayes, J.D. Contribution of NAD(P)H:quinone oxidoreductase 1 to protection against carcinogenesis, and regulation of its gene by the Nrf2 basic-region leucine zipper and the arylhydrocarbon receptor basic helix-loop-helix transcription factors. Mutat. Res. 555, 149–171 (2004).
Siegel, D. et al. Rapid polyubiquitination and proteasomal degradation of a mutant form of NAD(P)H:quinone oxidoreductase 1. Mol. Pharmacol. 59, 263–268 (2001).
Siegel, D., McGuinness, S.M., Winski, S.L. & Ross, D. Genotype-phenotype relationships in studies of a polymorphism in NAD(P)H:quinone oxidoreductase 1. Pharmacogenetics 9, 113–121 (1999).
Garte, S. et al. Biomarkers of exposure and effect in Bulgarian petrochemical workers exposed to benzene. Chem. Biol. Interact. 153–154, 247–251 (2005).
Rothman, N. et al. Benzene poisoning, a risk factor for hematological malignancy, is associated with the NQO1 609C → T mutation and rapid fractional excretion of chlorzoxazone. Cancer Res. 57, 2839–2842 (1997).
Krajinovic, M., Sinnett, H., Richer, C., Labuda, D. & Sinnett, D. Role of NQO1, MPO and CYP2E1 genetic polymorphisms in the susceptibility to childhood acute lymphoblastic leukemia. Int. J. Cancer 97, 230–236 (2002).
Larson, R.A. et al. Prevalence of the inactivating 609C → T polymorphism in the NAD(P)H:quinone oxidoreductase (NQO1) gene in individuals with primary and therapy-related myeloid leukemia. Blood 94, 803–807 (1999).
Naoe, T. et al. Analysis of genetic polymorphism in NQO1, GST-M1, GST-T1, and CYP3A4 in 469 Japanese individuals with therapy-related leukemia/ myelodysplastic syndrome and de novo acute myeloid leukemia. Clin. Cancer Res. 6, 4091–4095 (2000).
Smith, M.T. et al. Low NAD(P)H:quinone oxidoreductase activity is associated with increased risk of leukemia with MLL translocations in infants and children. Blood 100, 4590–4593 (2002).
Wiemels, J.L. et al. A lack of a functional NAD(P)H:quinone oxidoreductase allele is selectively associated with pediatric leukemias that have MLL fusions. United Kingdom Childhood Cancer Study Investigators. Cancer Res. 59, 4095–4099 (1999).
Krajinovic, M. et al. Polymorphisms in genes encoding drugs and xenobiotic metabolizing enzymes, DNA repair enzymes, and response to treatment of childhood acute lymphoblastic leukemia. Clin. Cancer Res. 8, 802–810 (2002).
Fowke, J.H. et al. Oral contraceptive use and breast cancer risk: modification by NAD(P)H:quinone oxoreductase (NQO1) genetic polymorphisms. Cancer Epidemiol. Biomarkers Prev. 13, 1308–1315 (2004).
Menzel, H.J. et al. Association of NQO1 polymorphism with spontaneous breast cancer in two independent populations. Br. J. Cancer 90, 1989–1994 (2004).
Sarmanova, J. et al. Breast cancer: role of polymorphisms in biotransformation enzymes. Eur. J. Hum. Genet. 12, 848–854 (2004).
Goode, E.L. et al. Effect of germ-line genetic variation on breast cancer survival in a population-based study. Cancer Res. 62, 3052–3057 (2002).
Minotti, G., Menna, P., Salvatorelli, E., Cairo, G. & Gianni, L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol. Rev. 56, 185–229 (2004).
Fitzgibbons, P.L. et al. Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. Arch. Pathol. Lab. Med. 124, 966–978 (2000).
Siemankowski, L.M., Morreale, J., Butts, B.D. & Briehl, M.M. Increased tumor necrosis factor-alpha sensitivity of MCF-7 cells transfected with NAD(P)H:quinone reductase. Cancer Res. 60, 3638–3644 (2000).
Lavin, M.F. & Gueven, N. The complexity of p53 stabilization and activation. Cell Death Differ. 13, 941–950 (2006).
Sablina, A.A. et al. PM. The antioxidant function of the p53 tumor suppressor. Nat. Med. 11, 1306–1313 (2005).
Wu, Z.H., Shi, Y., Tibbetts, R.S. & Miyamoto, S. Molecular linkage between the kinase ATM and NF-kappaB signaling in response to genotoxic stimuli. Science 311, 1141–1146 (2006).
Perik, P.J. et al. Circulating apoptotic proteins are increased in long-term disease-free breast cancer survivors. Acta Oncol. 45, 175–183 (2006).
Berberoglu, U., Yildirim, E. & Celen, O. Serum levels of tumor necrosis factor alpha correlate with response to neoadjuvant chemotherapy in locally advanced breast cancer. Int. J. Biol. Markers 19, 130–134 (2004).
Fossati, R. et al. Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women. J. Clin. Oncol. 16, 3439–3460 (1998).
A'Hern, R.P., Smith, I.E. & Ebbs, S.R. Chemotherapy and survival in advanced breast cancer: the inclusion of doxorubicin in Cooper type regimens. Br. J. Cancer 67, 801–805 (1993).
Clarke, M. et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 366, 2087–2106 (2005).
Estevam, F.R., Augusto, S.F., Rodrigues, S.A., Pinheiro, M.R. & Monteiro, A.F. Apoptosis and production of TNF-alpha by tumor-associated inflammatory cells in histological grade III breast cancer. Cancer Immunol. Immunother. 54, 671–676 (2005).
Asher, G. & Shaul, Y. P53 proteasomal degradation: poly-ubiquitination is not the whole story. Cell Cycle 4, 1015–1018 (2005).
Kovalenko, A. & Wallach, D. If the prophet does not come to the mountain: dynamics of signaling complexes in NF-kappaB activation. Mol. Cell 22, 433–436 (2006).
Janssens, S. & Tschopp, J. Signals from within: the DNA-damage-induced NF-kappaB response. Cell Death Differ. 13, 773–784 (2006).
Parkin, D.M., Bray, F., Ferlay, J. & Pisani, P. Global cancer statistics, 2002. CA Cancer J. Clin. 55, 74–108 (2005).
Arrigo, A.P. et al. Cytotoxic effects induced by oxidative stress in cultured mammalian cells and protection provided by Hsp27 expression. Methods 35, 126–138 (2005).